Improving the efficacy and targeting of letrozole for the control of breast cancer: in vitro and in vivo studies
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026
DOI: 10.1007/s00210-025-04634-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Shahira F El Menshawe und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, El-Shahid/Shehata Ahmed Hijaz St, Beni Suef, Egypt. Hauptthemen laut MEDLINE: Letrozole, Antineoplastic Agents, Breast Neoplasms, Mammary Neoplasms, Experimental. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beni Suef University.
Abstract (Originalsprache)
Letrozole (LTZ) is one of the most widely used treatments for breast cancer (BC). However, several issues can affect its effectiveness and bioavailability when administered orally, including low solubility and uncontrolled release. The primary aim of this study is to develop a hydrogel containing LTZ-loaded invasomes (LLI). This formulation is designed to enhance LTZ’s sustainability, permeability, targeting, bioavailability, and efficacy as a potential treatment for BC. The optimized LLI formulation was established by evaluating various formulations using the Box-Behnken design, focusing on entrapment efficiency and particle size. The LLI hydrogel was created by combining this optimal formulation with 2% Carbopol and was characterized in vitro for viscosity, release kinetics, and permeation. The anti-cancer effects, targeting ability, and safety of the LLI hydrogel were assessed in vivo using the 7,12-dimethylbenz(a)anthracene-induced breast cancer rat model (DIBC). The selected LLI formulation contained 3% phospholipids, 2% ethanol, and 0.5% cineole. Compared to free LTZ, the LLI hydrogel improved LTZ sustainability and permeation by 61.58% and 3.55-fold, respectively. Additionally, the LLI hydrogel reduced tumor volume by 99.69% compared to the DIBC group. Moreover, the concentration of LTZ accumulated in the tumor was 9.36 times greater in the LLI hydrogel than in the oral LTZ group. The transdermal LLI hydrogel represents a promising and safe treatment option for BC. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, El-Shahid/Shehata Ahmed Hijaz St, Beni Suef, Egypt.
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, El-Shahid/Shehata Ahmed Hijaz St, Beni Suef, Egypt. Amr_g@pharm.bsu.edu.eg.
Förderung
- Beni Suef University
Zitieren
APA
Menshawe, S. F. E., Ahmed, S. E., Fouad, A. G., & Hassan, A. H. (2026). Improving the efficacy and targeting of letrozole for the control of breast cancer: in vitro and in vivo studies. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04634-6
Vancouver
Menshawe SFE, Ahmed SE, Fouad AG, Hassan AH. Improving the efficacy and targeting of letrozole for the control of breast cancer: in vitro and in vivo studies. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-025-04634-6
BibTeX
@article{Menshawe2026,
author = {Menshawe, Shahira F El and Ahmed, Seif E and Fouad, Amr Gamal and Hassan, Amira H},
title = {Improving the efficacy and targeting of letrozole for the control of breast cancer: in vitro and in vivo studies},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-025-04634-6}
}
EUVIMED